Therefore, the propensity of sitagliptin to be involved in clinically meaningful drug-drug interactions mediated by plasma protein binding displacement is very low
Data from trials with liraglutide and empagliflozin suggest that at least some of the drugs of these two classes could also reduce mortality
ABOM, Chief Medical Officer at eMed, who will share insights from the front lines of patient care, clinical support and innovation in this rapidly evolving space
299:1561-1573 [PubMed: 18378631] 102
Medication timing and dosing adjustments can also reduce risk
Due to the concern about the growing prevalence of unapproved GLP-1s on the market, the FDA issued warning letters to the following companies in December: The FDA warned the companies about potential violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act), even with the companies claiming some of their GLP-1 products were currently for research purposes only